Braveheart Bio registers Phase 3 trial of BHB-1893 for obstructive HCM
The trial will compare BHB-1893 to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy, with an estimated start in October 2026.
Braveheart Bio filed one new registry entry this week for its oHCM program.
- BHB-1893, a Phase 3 trial in adults with symptomatic obstructive hypertrophic cardiomyopathy, is listed as not yet recruiting, with the main purpose of finding out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy.1 The study, known as LIONHEART-HCM, has an estimated start date of 2026-10-31 and planned enrollment of 210 participants, with the primary outcome being change from baseline in peak oxygen uptake by cardiopulmonary exercise testing at week 24.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.